ESPGHAN/ESPEN/ESPR/CSPEN Guidelines on Pediatric Parenteral Nutrition: Complications
Corina Hartman,Raanan Shamir,Venetia Simchowitz,Szimonetta Lohner,Wei Cai,Támas Décsi,Espghan,Espen,Espr
DOI: https://doi.org/10.1016/j.clnu.2018.06.956
IF: 7.643
2018-01-01
Clinical Nutrition
Abstract:Literature search Timeframe: publications from 2004 until December 2014 were reviewed Type of publications: The search was restricted to infants and children (0–18 years) but not limited by publication form or language. Key words: The search was conducted in Ovid Medline using both MeSH terms and text words for “parenteral nutrition complications”. In parallel an expert search was conducted focusing on specific subtopics of parenteral nutrition complications. Titles and abstracts retrieved by electronic and expert searches were first screened by a collaborator of Cochrane Hungary and clearly irrelevant abstracts were removed. Subsequently, members of the Working Group screened titles and abstracts for eligibility. Full texts of all potentially relevant manuscripts were retrieved and assessed.Tabled 1Table 14.1: Recommendations for the prevention of complicationsR 14.1Any child with IF and an indwelling CVC is at significant risk for CRBSI and, accordingly, any fever (temperature >38.5 or rise >1 °C), or change in clinical or laboratory parameters should raise the suspicion of CLABSI until proven otherwise (LOE 2+, RG B, strong recommendation)R 14.2Paired quantitative blood cultures taken simultaneously from both the CVC and a peripheral vein should ideally be obtained when a CRBSI is suspected and before the start of antibiotic therapy (extrapolated from adult studies rated as LOE 2++, RG B, strong recommendation)R 14.3The most readily available technique to confirm CRBSI without catheter removal is the calculation of DTP (differential time to diagnosis) between blood cultures drawn from the catheter and from a peripheral vein or separate lumen (extrapolated from adult studies rated as LOE 2++, RG B, strong recommendation)R 14.4Empirical antibiotic therapy for CRBSI should usually include coverage for Gram-positive coagulase-negative or –positive staphylococci and Gram-negative bacilli (extrapolated from adult studies rated as LOE 2++, RG B, strong recommendation)R 14.5The duration of antimicrobial therapy for CRBSI with retained catheter is generally 10–14-days, assuming clinical and microbiological response within 48–72 h and no evidence of complications (extrapolated from adult studies rated as LOE 2++, RG B, strong recommendation).R 14.6Removal of the CVC is recommended in the presence of clinical deterioration or persisting or relapsing bacteremia, presence of suppurative complications or for particular infectious agents (extrapolated from adult studies rated as LOE 2++, RG B, strong recommendation)R 14.7Thrombotic catheter occlusion and CVC related thrombosis require thorough investigation and treatment as they may be associated with significant morbidity (LOE 2−, RG B, strong recommendation)R 14.8Fibrinolytics are the drug class of choice for treating thrombus-occluded catheters. Tissue plasminogen activator (tPA, alteplase) is currently the recommended agent; however, urokinase and recombinant urokinase (rUK) can also be used (LOE 2+, RG B, strong recommendation)R 14.9The recommended management of acute and symptomatic CVC-related thrombosis depends on the requirement for the CVC and usually requires antithrombotic medication (LOE 2+, RG B, strong recommendation)R 14.10Proper positioning of the catheter tip and immediate investigation when catheter breakage or fluid extravasation are suspected should be implemented in order to prevent the occurrence of significant morbidity (LOE 4, RG 0, strong recommendation)R 14.11Appropriate measures to secure the catheter in place and education for users on correct maintenance and safety of the catheter are strongly recommended (GPP, strong recommendationR 14.12PN should be administered wherever possible using an admixture formulation validated by a licensed manufacturer or suitably qualified institution (GPP, strong recommendation)R 14.13A matrix table should be sought from the supplier of the formulation detailing permissible limits for additions of electrolytes and other additives (GPP, strong recommendation)R 14.14Alternative ingredients should not be substituted without expert advice or repeat validation (GPP, strong recommendation)R 14.15Phosphate should be added in an organic-bound form to prevent the risk of calcium-phosphate precipitation (GPP, strong recommendation)R 14.16If inorganic phosphate is used, stability matrices and order of mixing must be strictly adhered to (GPP, strong recommendation)R 14.17When ‘2 in 1’ admixtures with Y-site lipids added are used, addition of lipids should be fully validated by the manufacturer or accredited laboratory, or the lipid infused through an alternative line (GPP, strong recommendation)R 14.18Mixing of medications with PN in administration lines should be avoided unless validated by the manufacturer or accredited laboratory (GPP, strong recommendation)R 14.19Multi-layer bags which are impermeable to oxygen are recommended for PN administration (GPP, strong recommendation)R 14.20Light protection is recommended for both PN bags and administration sets (LOE 3, RG 0, strong recommendation)R 14.21The recommended delivery site for PN is via a central line; however peripheral PN can also be given for short periods (LOE 3; RG 0, strong recommendation)R 14.22The osmolarity of peripheral PN solution should be kept less than 900 mosmol/l (LOE 3; RG 0, conditional recommendation)R 14.23In children on home PN, regular measurements of urinary calcium, plasma calcium, phosphorus, parathyroid hormone and 25-OH vitamin D concentrations and serum alkaline phosphatase activity should be performed (LOE 2+, RG B, strong recommendation)R 14.24Ingredients with the lowest amount of aluminum are advocated for the preparation of parenteral nutrition solutions provided to patients receiving PN (LOE 2++, RG B, strong recommendation)R 14.25Regular assessment of bone mineralization should be performed (LOE 2−, RG B, strong recommendation)R 14.26The risk of liver disease may be decreased by reducing patient-related and PN-related risk factors (LOE 2+, RG B, strong recommendation)R 14.27In patients with intestinal failure-associated liver disease, maximizing enteral intake as tolerated may improve liver disease outcome (GPP, strong recommendation)R 14.28In patients on long-term and home PN, cyclic of PN infusion is recommended as soon as metabolic and fluid status allows (LOE 3, RG 0, strong recommendation)R 14.29Pure soybean-based lipid emulsions should be avoided in the presence of cholestasis (LOE 3, RG 0, strong recommendation)R 14.30The use of mixed LEs may be encouraged in IF patients for long term PN (LOE 3, RG 0, conditional recommendation)R 14.31The initiation of ursodeoxycholic acid may be considered in the presence of biochemical signs of cholestasis (LOE 3, RG 0, conditional recommendation)R 14.32Early referral to an experienced pediatric intestinal failure rehabilitation/transplantation centre is recommended in infants/children with intestinal failure-associated liver disease (GPP, strong recommendation)R 14.33All patients on long term PN require regular monitoring of growth and body composition (LOE 2−, RG B, strong recommendation) Open table in a new tab